Enanta Pharmaceuticals Inc (NASDAQ:ENTA) Expected to Post Quarterly Sales of $60.59 Million

Equities research analysts expect that Enanta Pharmaceuticals Inc (NASDAQ:ENTA) will announce $60.59 million in sales for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Enanta Pharmaceuticals’ earnings, with the highest sales estimate coming in at $62.44 million and the lowest estimate coming in at $58.63 million. Enanta Pharmaceuticals posted sales of $69.89 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 13.3%. The company is scheduled to issue its next earnings results on Wednesday, February 5th.

On average, analysts expect that Enanta Pharmaceuticals will report full-year sales of $179.79 million for the current year, with estimates ranging from $166.29 million to $187.24 million. For the next year, analysts anticipate that the business will post sales of $161.85 million, with estimates ranging from $145.32 million to $171.22 million. Zacks’ sales averages are an average based on a survey of research firms that cover Enanta Pharmaceuticals.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings results on Thursday, November 21st. The biotechnology company reported $0.44 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.56 by ($0.12). The business had revenue of $51.30 million for the quarter, compared to the consensus estimate of $55.95 million. Enanta Pharmaceuticals had a net margin of 22.60% and a return on equity of 10.46%. Enanta Pharmaceuticals’s revenue for the quarter was down 23.7% on a year-over-year basis. During the same period in the prior year, the business posted $1.30 EPS.

ENTA has been the subject of several analyst reports. BidaskClub upgraded shares of Enanta Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday. Zacks Investment Research downgraded Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, November 22nd. Berenberg Bank set a $130.00 target price on Enanta Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, September 18th. ValuEngine raised Enanta Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Finally, JPMorgan Chase & Co. cut Enanta Pharmaceuticals from a “neutral” rating to an “underweight” rating and dropped their target price for the company from $86.00 to $57.00 in a report on Thursday, September 26th. Three analysts have rated the stock with a sell rating, one has assigned a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $96.50.

Enanta Pharmaceuticals stock opened at $64.08 on Friday. The company has a market capitalization of $1.26 billion, a PE ratio of 29.00 and a beta of 0.90. The firm has a fifty day simple moving average of $61.83 and a two-hundred day simple moving average of $73.38. Enanta Pharmaceuticals has a twelve month low of $57.15 and a twelve month high of $106.80.

Institutional investors have recently modified their holdings of the company. Man Group plc increased its stake in shares of Enanta Pharmaceuticals by 181.3% in the third quarter. Man Group plc now owns 295,954 shares of the biotechnology company’s stock worth $17,781,000 after buying an additional 190,743 shares during the period. Squarepoint Ops LLC raised its holdings in Enanta Pharmaceuticals by 379.5% during the 3rd quarter. Squarepoint Ops LLC now owns 34,498 shares of the biotechnology company’s stock valued at $2,073,000 after buying an additional 27,303 shares during the last quarter. Voloridge Investment Management LLC purchased a new stake in Enanta Pharmaceuticals during the 3rd quarter valued at $719,000. Krensavage Asset Management LLC boosted its position in Enanta Pharmaceuticals by 4.0% during the 3rd quarter. Krensavage Asset Management LLC now owns 498,874 shares of the biotechnology company’s stock valued at $29,972,000 after buying an additional 19,298 shares during the period. Finally, Granahan Investment Management Inc. MA boosted its position in Enanta Pharmaceuticals by 3.3% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 148,604 shares of the biotechnology company’s stock valued at $8,928,000 after buying an additional 4,805 shares during the period. Hedge funds and other institutional investors own 89.79% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.

Read More: Are sell-side analysts objective?

Get a free copy of the Zacks research report on Enanta Pharmaceuticals (ENTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.